WuXi AppTec Co., Ltd. (WUXIF) Stock Price & Analysis
WuXi AppTec Co., Ltd. (WUXIF) — price $25.06 (0.00%), as of the Nov 19, 2026 trading session; market cap $76.1B.
Educational signal · not a buy or sell recommendation · How to read this
WuXi AppTec Co., Ltd. · WUXIF · Healthcare · Diagnostics & Research
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States,…
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $25.06 | |
| Change on the day | 0.00% | |
| 52-week range | $13.60–$29.10 | |
| Market capitalisation | $76.1B | — |
| Price / earnings (trailing) | 15.46 | |
| Shares traded on the day | 100 | |
| Beta (volatility vs the S&P 500) | 0.61 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for WuXi AppTec Co. (WUXIF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is WuXi AppTec Co. (WUXIF), and what does it report?
Short answer
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States,… WuXi AppTec Co., Ltd. (WUXIF) is classified as Healthcare / Diagnostics & Research. Headquarters: 288 Fute Zhong Road, Shanghai, 200131, China. It employs 33,834 people. In Q2 FY2026 it reported revenue of CN¥16.39B and net income of CN¥6.38B. The market values it at $76.1B.
What do the latest results show for WuXi AppTec Co. (WUXIF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CN¥16.39B. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CN¥16.39B | CN¥6.38B | CN¥2.17 (diluted) |
| Q1 FY2026 | CN¥12.44B | CN¥4.65B | CN¥1.58 (diluted) |
| Q4 FY2025 | CN¥12.60B | CN¥7.08B | CN¥2.44 (diluted) |
| Q3 FY2025 | CN¥12.04B | CN¥3.51B | CN¥1.21 (diluted) |
What are the financial strengths and risks for WuXi AppTec Co. (WUXIF)?
Short answer · as of
The distress and quality screens read Altman Z 12.33 · Piotroski F 5. Trailing ratios: ROE 30.0% · ROA 14.3% · current ratio 3.43.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held WUXIF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported WUXIF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about WuXi AppTec Co. (WUXIF)?
- WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability
- Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles River
- Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Drug Development ROI
What Investors Ask About WuXi AppTec Co. (WUXIF) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the WUXIF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is WUXIF a good stock to buy?
Stock Expert AI does not rate WUXIF buy, sell or hold. WuXi AppTec Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the WUXIF stock price today?
The last price recorded for WuXi AppTec Co., Ltd. (WUXIF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does WuXi AppTec Co., Ltd. contribute to drug development?
WuXi AppTec Co., Ltd. plays a pivotal role in global drug development by offering comprehensive contract research, development, and manufacturing (CRDMO) services.
What are the key factors to evaluate for WUXIF?
Evaluate WUXIF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Expanding CRDMO Services: The global demand for outsourced R&D and manufacturing services continues to grow, driven by pharmaceutical companies seeking to enhance efficiency and access specialized capabilities. Not financial advice.
How frequently does WUXIF data refresh on this page?
WUXIF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven WUXIF's recent stock price performance?
WuXi AppTec Co., Ltd. (WUXIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive CRDMO capabilities covering the entire drug development lifecycle. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WUXIF overvalued or undervalued right now?
The trailing P/E of WuXi AppTec Co., Ltd. (WUXIF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research WUXIF before investing?
Before investing in WuXi AppTec Co., Ltd. (WUXIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 15 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com